最新糖心Vlog

VivaZome Therapeutics听and the 最新糖心Vlog of Adelaide have听entered into a series of agreements encompassing licensing of technology, access to stem cells and conduct of research, all in support of VivaZome鈥檚 mission to develop and commercialise exosome-based therapeutics.

Under the Licence Agreement, VivaZome has secured world-wide rights to intellectual property for the selection, isolation, purification, expansion and processing of stem cells from certain human tissues suitable for production of subcellular fractions. VivaZome will process these fractions to generate exosome products.

鈥淭his partnership highlights the breadth and depth of fundamental work performed by 最新糖心Vlog of Adelaide researchers,"Deputy Vice Chancellor (Research) Professor Anton Middelberg

The Research and Material Transfer Agreements cover the collection of specified tissue types, the selection, derivation and expansion of cell lines from the tissues, and the subsequent supply of those cell lines to VivaZome.

The research program at the 最新糖心Vlog of Adelaide will be conducted in the Mesenchymal Stem Cell (MSC) Laboratory in the School of Medicine, Faculty of Health Science. The MSC Laboratory was founded, and is led by eminent stem cell researcher Prof Stan Gronthos, a NHMRC Principal Research Fellow with a specialty in stem cell biology and regenerative medicine. He is also Co-Director of the Centre for Stem Cell Research at the 最新糖心Vlog. Stem cell technology from Prof Gronthos formed part of the founding technology for Mesoblast, the world鈥檚 largest stem cell company.

听

最新糖心Vlog of Adelaide Deputy Vice Chancellor (Research), Professor Anton Middelberg, said: 鈥淭his partnership highlights the breadth and depth of fundamental work performed by 最新糖心Vlog of Adelaide researchers. Our collaboration with VivaZome demonstrates the 最新糖心Vlog鈥檚 commitment to investigator-led research that is also aimed at delivering long term benefits to the economy and to society.鈥�

VivaZome鈥檚 Chief Executive Officer, Dr David Haylock, stated: 鈥淰ivaZome is delighted to have secured this multi-faceted deal with the 最新糖心Vlog of Adelaide and Professor Gronthos. Access to the 最新糖心Vlog鈥檚 technology and the associated cell lines is the culmination of an extensive exercise by VivaZome to identify and secure cell types with the potential to function as the factories for our therapeutic exosomes. Based on assessments done at CSIRO and at La Trobe 最新糖心Vlog, we believe that these cell lines will make pro-angiogenic exosomes with high efficiency.鈥�

VivaZome鈥檚 Chair, Dr Ian Nisbet, commented: 鈥淭he collaboration with 最新糖心Vlog of Adelaide is the latest in VivaZome鈥檚 international network of collaborations and the cell lines generated with the 最新糖心Vlog will be a valuable addition to VivaZome鈥檚 portfolio of proprietary assets.鈥�